NIH's dedicated K23 trial pathway was associated with more K-trial leadership but no detectable gain in new trials
Haining Wang, Hengyi Fu, Zuoyu Tian
This paper evaluates the impact of NIH's K23 trial pathway on trial leadership, finding increased K-trial leadership but no significant increase in new trials.
bioRxiv · Oct 21, 2026 · PreprintScientific Communication & Education